93 related articles for article (PubMed ID: 23381936)
1. Population pharmacokinetics of atorvastatin and its active metabolites in children and adolescents with heterozygous familial hypercholesterolemia: selective use of informative prior distributions from adults.
Knebel W; Gastonguay MR; Malhotra B; El-Tahtawy A; Jen F; Gandelman K
J Clin Pharmacol; 2013 May; 53(5):505-16. PubMed ID: 23381936
[TBL] [Abstract][Full Text] [Related]
2. Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite.
Narwal R; Akhlaghi F; Asberg A; Hermann M; Rosenbaum SE
Clin Pharmacokinet; 2010 Oct; 49(10):693-702. PubMed ID: 20818835
[TBL] [Abstract][Full Text] [Related]
3. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Dostalek M; Sam WJ; Paryani KR; Macwan JS; Gohh RY; Akhlaghi F
Clin Pharmacokinet; 2012 Sep; 51(9):591-606. PubMed ID: 22775412
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia.
Macpherson M; Hamrén B; Braamskamp MJ; Kastelein JJ; Lundström T; Martin PD
Eur J Clin Pharmacol; 2016 Jan; 72(1):19-27. PubMed ID: 26387811
[TBL] [Abstract][Full Text] [Related]
5. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS.
Hermann M; Christensen H; Reubsaet JL
Anal Bioanal Chem; 2005 Jul; 382(5):1242-9. PubMed ID: 15933849
[TBL] [Abstract][Full Text] [Related]
6. Effect of itraconazole on the pharmacokinetics of atorvastatin.
Kantola T; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
[TBL] [Abstract][Full Text] [Related]
7. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
Lau YY; Huang Y; Frassetto L; Benet LZ
Clin Pharmacol Ther; 2007 Feb; 81(2):194-204. PubMed ID: 17192770
[TBL] [Abstract][Full Text] [Related]
8. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
[TBL] [Abstract][Full Text] [Related]
9. The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease.
He BX; Shi L; Qiu J; Zeng XH; Zhao SJ
J Clin Pharmacol; 2014 Apr; 54(4):462-7. PubMed ID: 24214373
[TBL] [Abstract][Full Text] [Related]
10. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin.
Stern RH; Yang BB; Horton M; Moore S; Abel RB; Olson SC
J Clin Pharmacol; 1997 Sep; 37(9):816-9. PubMed ID: 9549635
[TBL] [Abstract][Full Text] [Related]
11. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Whitfield LR; Porcari AR; Alvey C; Abel R; Bullen W; Hartman D
J Clin Pharmacol; 2011 Mar; 51(3):378-88. PubMed ID: 20413454
[TBL] [Abstract][Full Text] [Related]
12. Novel delivery systems of atorvastatin should be evaluated for pharmacodynamics instead of pharmacokinetics.
Date AA; Nagarsenker MS
J Pharm Pharmacol; 2007 Nov; 59(11):1583-4. PubMed ID: 17976271
[No Abstract] [Full Text] [Related]
13. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
Ulvestad M; Skottheim IB; Jakobsen GS; Bremer S; Molden E; Asberg A; Hjelmesæth J; Andersson TB; Sandbu R; Christensen H
Clin Pharmacol Ther; 2013 Mar; 93(3):275-82. PubMed ID: 23361102
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of atorvastatin.
Lennernäs H
Clin Pharmacokinet; 2003; 42(13):1141-60. PubMed ID: 14531725
[TBL] [Abstract][Full Text] [Related]
15. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase.
Whitfield LR; Stern RH; Sedman AJ; Abel R; Gibson DM
Eur J Drug Metab Pharmacokinet; 2000; 25(2):97-101. PubMed ID: 11112089
[TBL] [Abstract][Full Text] [Related]
16. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
Shin KH; Kim TE; Kim SE; Lee MG; Song IS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
J Cardiovasc Pharmacol; 2011 Nov; 58(5):492-9. PubMed ID: 21765368
[TBL] [Abstract][Full Text] [Related]
17. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers.
Bullman J; Nicholls A; Van Landingham K; Fleck R; Vuong A; Miller J; Alexander S; Messenheimer J
Epilepsia; 2011 Jul; 52(7):1351-8. PubMed ID: 21635243
[TBL] [Abstract][Full Text] [Related]
18. Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats.
Dong J; Yu X; Wang L; Sun YB; Chen XJ; Wang GJ
Acta Pharmacol Sin; 2008 Oct; 29(10):1247-52. PubMed ID: 18817631
[TBL] [Abstract][Full Text] [Related]
19. Population analyses of atorvastatin clearance in patients living in the community and in nursing homes.
Schwartz JB; Verotta D
Clin Pharmacol Ther; 2009 Nov; 86(5):497-502. PubMed ID: 19571802
[TBL] [Abstract][Full Text] [Related]
20. A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes.
Bucher J; Riedmaier S; Schnabel A; Marcus K; Vacun G; Weiss TS; Thasler WE; Nüssler AK; Zanger UM; Reuss M
BMC Syst Biol; 2011 May; 5():66. PubMed ID: 21548957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
